MUC1 (Mucin 1)

Direct oral anticoagulants represent a valuable therapeutic option with multiple advantages. Their potential antineoplastic effects-particularly those of factor XI inhibitors currently under investigation-may provide additional benefits in cancer-associated thrombosis.

[This retracts the article DOI: 10.3389/fphar.2024.1345645.].

Ongoing phase I and II trials explore combination therapies with checkpoint inhibitors and antibody-drug conjugates to overcome these barriers. This review examines the current landscape, mechanisms, and challenges of breast cancer vaccines, highlighting their potential to transform oncology through personalized, less invasive strategies.

The results of WB and dual‑luciferase reporter assays demonstrated that miR‑29a regulated the β‑catenin/c‑Myc pathway and the viability of HUVECs in HUVECs by directly binding to ITGB1. Therefore, miR‑29a may serve as a potential therapeutic target for IH.

This study provides the first detailed protocol for establishing primary CMG epithelial cultures and validates their suitability as a reference model for future oncological studies. Overall, this platform supports translational research, including drug testing and biomarker discovery, contributes to personalized veterinary therapies and enhanced understanding of mammary gland pathology in both dogs and humans.

Furthermore, we highlight the development of highly promising alumina- and silica-based platforms for drug delivery (e.g., chemotherapeutics, photosensitizers, or gene delivery agents) in cancer. Ultimately, by providing a comprehensive overview alongside a critical analysis, we demonstrate that such nanostructures represent promising platforms for potential clinical translation in cancer medicine, helping to mitigate the limitations of conventional cancer therapies.

Moreover, by incorporating a strand-displacement recognition strategy, quantitative detection of MUC1 was further demonstrated. By integrating self-propulsion with stable fluorescence signaling, the JMMs-FNDs sensing platform enabling efficient and highly sensitive fluorescence biodetection.

Our findings indicated that hsa_circ_0001756 could promote BC malignant progression through the miR-584-5p/TRAF6 signaling axis. Especially, hsa_circ_0001756 in serum holds promise as a biomarker for BC screening and diagnosis.

It demonstrated favorable analytical performance with a wide linear range from 102 to 106 cells per mL and a detection limit of 31 cells per mL (S/N = 3), equivalent to a single-cell detection level on the cytosensor considering the sample volume and capture efficiency. This ECL cytosensor shows reliable detection performance in complex matrices, displaying great application prospects in biological detection and clinical diagnosis.

Major challenges include heterogeneity and temporal variability of TAA expression, cytokine release syndrome (CRS) mitigation strategies, pharmacodynamic optimization, and delivery methods to maximize tumor bioavailability while limiting systemic toxicity. This review details the molecular mechanisms, preclinical evidence, clinical trial outcomes, and translational challenges for BsAbs in breast cancer, highlighting their transformative potential in expanding immunotherapeutic efficacy beyond current limitations.

Recovery studies in 10% human serum spiked with MCF-7 cells (as a model CTC system) showed excellent accuracy (96.5-104.2%) with RSD ≤ 4.5%. Collectively, these results demonstrate strong analytical performance for MCF-7 model CTCs in buffered suspensions and in a spiked (10%) serum matrix, supporting the AuND/dual-aptamer platform as a proof-of-concept CTC biosensing strategy; validation using patient-derived CTCs in whole-blood samples will be required in future studies to establish clinical utility.

This Review focuses on the roles of MUC1 and the oncogenic M1C protein in reproductive fitness and barrier tissue protection that in settings of chronic inflammation promote pan-cancer progression and treatment resistance. Also highlighted are therapeutic approaches targeting MUC1 and M1C that are under clinical and pre-clinical development.